Pivotal-Point Tracking Supernus Pharmaceuticals (SUPN): Price Target Skyrockets after Piper Sandler Upgrade – Parkinson's Drug Onapgo as a new Revenue Star!
Reading Time: 1 minute
Supernus Pharmaceuticals is a biopharmaceutical company specializing in the development and marketing of products for the treatment of central nervous system disorders. This includes neurological conditions such as epilepsy, migraines, and Parkinson's disease, as well as psychiatric disorders like attention deficit hyperactivity disorder (ADHD) and postpartum depression (PPD). The business model aims to close therapeutic gaps and provide added value to patients through innovative formulations of known active ingredients and novel substances. The...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
